Download now: Cannabis Cash

The B-5 System: How to Buy Biotechs for Pennies Before They Go Public

Written by Brian Hicks
Posted September 30, 2021

On April 19, 2020, you could’ve done something most investors only dream about.

On that day, you could’ve invested alongside stock expert Jeff Siegel in a tiny biotech startup called MindMed.

He bought in at $0.25 a share.

A year later, MindMed was trading for nearly $6.

Yes, you could’ve done the exact same thing. I’ll explain how in a minute.

For Jeff, it was the trade of a lifetime… a gain of 2,300% in just 12 months. 

Believe it or not, Jeff considered it an easy score. 

You see, at the time of Jeff’s investment, MindMed was pioneering a new treatment for anxiety, depression, and addiction. It was developing psychedelics to combat those dreaded diseases. 

But the company’s stock wasn’t trading on any public exchanges, so regular investors couldn’t invest in it. 

Even before the company went public, it was getting serious media coverage.

Big media outlets like Forbes and Fortune were covering MindMed (well after Jeff’s investment), with the former saying:

Statistics report a frightening rise in addiction and anxiety during the pandemic, and new forms of medicine will be needed to alleviate this.

The Wall Street Journal noted:

MindMed is developing what will become the “antibiotic for addiction.”

More importantly, Jeff knew that the prolonged COVID-19 lockdowns, school shutdowns, and massive unemployment were going to cause another pandemic in anxiety, depression, and suicides. 

In fact, new studies report that depression in the U.S. is spiking beyond experts’ previous predictions — with rates rising 400% higher in 2021 than in 2019. 

Jeff knew new therapies for mental illness were going to be in high demand.

And that’s one of the reasons Jeff invested in MindMed in the early stages of its life.

But here’s why I’m contacting you today...

I’m here to tell you that opportunities to invest in these ground-floor biotech stocks are about to go into overdrive. 

As you read this, small medical companies are working overtime in search of cures and treatments for COVID-19. They know the COVID crisis is going to be with us for a very long time, and it’s setting us up for a bonanza in early-stage investments in biotechnology stocks — investments where you can get in for pennies on the dollar and then sell a year later for massive gains.

Jeff has done this over and over again.

Years before COVID and MindMed, cannabis companies were in a similar situation. Companies like Canopy Growth, Aphria, and Cresco Labs were trading as penny stocks when Jeff invested in them. 

But Jeff knew the medical benefits of cannabis to treat anxiety, depression, and PTSD would eventually become accepted by the medical establishment… and, more importantly, by the mainstream investing public, pushing these stocks much higher — and I mean a lot higher.

Jeff is a big advocate for veterans’ rights and mental health awareness. 

Nearly 12 times more veterans of the Afghanistan and Iraq wars have died by suicide than have died in combat. In fact, between 2008–2019, over 60,000 veterans committed suicide… more than all the combat deaths in the Vietnam War. 

For Jeff, this is unacceptable — as it is for me, the son of a Marine who fought in Vietnam and the grandson of an Army infantryman who was wounded at Anzio. 

Jeff made it his mission to find solutions. 

That’s why he was so hot on investing in cannabis companies. And boy, did he and his members make a killing. 

Aphria, for example was trading for less than $1.25 when Jeff recommended it in early 2016. A few years later, when pot stocks were the darlings of Wall Street, he sold it above $20 a share. 

The same thing happened with Canopy Growth. Canopy is one of the leading cannabis stocks in the world, with a current market valuation of over $7 billion.

But it was nowhere near that price when Jeff bought it in 2015 for just $1.60 a share. Four years after Jeff bought it, Canopy was trading at nearly $70 a share. 

Jeff and his followers eventually sold their positions for a gain of 3,015%. 

Although Jeff is still bullish on cannabis stocks, he’s moved on to the next generation of therapeutics to 1) alleviate depression, anxiety, and suicide, and 2) help combat the COVID-19 crisis in all its forms, whether that’s mental illness or actually fighting the disease itself.

And that brings me to my next point.

Jeff is laser-focused on the blockbusters being developed in the biotechnology sector.

Countless companies are working on life-changing innovations like 3D bioprinting, gene engineering, and artificial intelligence in medicine.

For 27 years, Jeff’s been developing an extensive network of personal contacts deep inside the biotech industry, and I can tell you from experience...

The game-changing advances happening in biotech right now give us a never-ending parade of trading opportunities.

And he’s developed a system he calls “B-5.

B-5 pinpoints private biotech companies to invest in… before they go public!

That’s right — Jeff has an easy-to-understand, easy-to-follow system for you to invest in these private companies before they go public, just like he did with MindMed.

And B-5 is incredibly powerful in the biotech market.

Now, I know what you’re probably thinking...

When most people hear about biotech profits, they expect to hear about FDA approvals, patents, or new drug launches.

B-5 has nothing to do with any of that. 

We’re not waiting for companies to make breakthroughs like Moderna, GW Pharmaceuticals, or Cardiff Oncology did.

We are getting in on the ground floor. 

As I write this, he has already closed 19 positions in 2021 without a single loser. Let me repeat that — not one loser in his closed 2021 portfolio thus far! 

So here’s the deal. Jeff has put together an exclusive presentation for you about B-5.

He explains it in detail so you’ll be able to understand all the ins and outs.

Plus, Jeff has a pipeline of companies he’s ready to invest in. 

I urge you to give it a look. You could make quite a bit of money.

All the best,

Brian Hicks Signature

Brian Hicks

Brian is a founding member and President of Angel Publishing and investment director for the income and dividend newsletter The Wealth Advisory. He writes about general investment strategies for Wealth Daily and Energy and Capital. Known as the "original bull on America," Brian is also the author of Profit from the Peak: The End of Oil and the Greatest Investment Event of the Century, published in 2008. In addition to writing about the economy, investments and politics, Brian is also a frequent guest on CNBC, Bloomberg, Fox, and countless radio shows. For more on Brian, take a look at his editor's page.

Hydrogen Fuel Cells: The Downfall of Tesla?